Skip to main content

How is Blincyto administered?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Dec 5, 2024.

Blincyto administration

Official answer

by Drugs.com

Blincyto (blinatumomab) is a cancer treatment given as a continuous IV infusion over 28 days. You then have a break with no treatment. This is called a treatment cycle which includes the treatment days and treatment-free days.

How many treatment cycles you have will depend on which type of acute lymphoblastic leukemia (ALL) you are treating.

MRD-positive B-cell Precursor ALL:

  • One induction cycle (28 days treatment, 14 days no treatment)
  • Up to three additional cycles for consolidation (28 days treatment, 14 days no treatment)

Relapsed or Refractory B-cell Precursor ALL:

  • Two induction cycles (28 days treatment, 14 days no treatment)
  • Three additional cycles for consolidation (28 days treatment, 14 days no treatment)
  • Up to four additional cycles of continued therapy (28 days treatment, 56 days no treatment)

B-cell Precursor ALL in the Consolidation Phase

  • A single cycle of Blincyto monotherapy in consolidation is 28 days of continuous infusion followed by a 14-day treatment-free interval (total 42 days)

Cycles may be interrupted due to adverse reactions.More detailed information on dosage and administration is available on the Blincyto Dosage page.

References

Read next

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

How much does Blincyto (blinatumomab) cost?

The cost of a Blincyto (blinatumomab) vial is approximately $5,427 per 35 microgram (mcg) single-dose vial for injection. The overall cost for your therapy will also depend upon the length of treatment. Most people do not pay out-of-pocket for the full price of Blincyto. Continue reading

Is Blincyto a type of immunotherapy?

Blincyto is a type of immunotherapy called a bispecific monoclonal antibody. This means that it binds to two different molecules at the same time – a protein called CD19 which exists on the surface of B-cell leukemia or lymphoma cells and a protein called CD3 which is expressed on T cells (a specific type of immune system cell). Blincyto may also be called a targeted treatment. Continue reading

Related medical questions

Drug information

Related support groups